NCT04094610 2025-11-19A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsTurning Point Therapeutics, Inc.Phase 1/2 Recruiting75 enrolled
NCT03997968 2024-12-24A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsCyteir Therapeutics, Inc.Phase 1/2 Completed169 enrolled
NCT02223052 2020-05-12Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCelgenePhase 1 Completed89 enrolled
NCT00948961 2016-06-27A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1Celldex TherapeuticsPhase 1/2 Completed70 enrolled
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts